Log In
Print this Print this

GBR 1302

  Manage Alerts
Collapse Summary General Information
Company Glenmark Pharmaceuticals Ltd.
DescriptionCD3/HER2 bispecific mAb
Molecular Target CD3 ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat HER2 expressing solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today